Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 25, 2008

Lilly's ALIMTA : European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer

Apr 11, 2008 - Approval Marks Third European Indication for ALIMTA

Eli Lilly and Company (NYSE: LLY) announced that European health authorities have approved the use of ALIMTA® (pemetrexed for injection) for a histologically-based use in the first-line treatment of advanced non-small-cell lung cancer (NSCLC), the most common form of lung cancer. This approval - the third for pemetrexed in Europe - follows an initial positive opinion issued by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on February 21, 2008.

The EMEA specifically approved pemetrexed in combination with cisplatin as a first-line treatment for NSCLC patients with other than predominantly squamous cell histology. Histology is the microscopic study of tissue and NSCLC is classified by its histology. Previously, all histologies were treated similarly... Lilly's Press Release -